why choose us

First received: May 18, 2023

Clinical Trial: A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance

Brief Summary: The purpose of this study to see how the brain absorbs, distributes, and gets rid of tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have spread to the brain, and to learn more about how cancer cells develop resistance to treatment.The researchers will do research tests to look for genetic differences between HER2+ breast cancer that has spread to the brain and progressed during treatment with tucatinib and cancers that are being treated with tucatinib for the first time.

Read more